Photocure ASA - New CFO Appointed
Oslo, Norway, October 22, 2026: Photocure ASA (OSE: PHO), the Bladder Cancer Company, is today announcing that Dennis Camporeale has been appointed as Chief Financial Officer, effective on Monday, October 26, 2026.
Dennis Camporeale brings 25 years of experience as senior healthcare investment banker and corporate finance leader across life science tools, diagnostics, medtech and broader healthcare. He most recently led the Life Science Tools and Diagnostics practice at Canaccord Genuity, advising boards and executive teams on capital raising, M&A, restructuring and strategic development. Alongside his advisory background, Mr. Camporeale brings meaningful operational experience from Ally Financial, where he helped transform GMAC from a captive finance subsidiary into a standalone public company. He supported the company's successful US IPO, international divestments and the development of the financial controls, governance structures and reporting processes required for a publicly listed organisation.
"I am delighted to welcome Dennis to Photocure as our new CFO. His experience across medtech, diagnostics and broader life sciences investment banking brings a valuable combination of industry insight, financial expertise and strategic perspective to the company," said Dan Schneider, CEO of Photocure. "As we continue to advance our growth strategy and broaden our reach to unlock the full potential of our emerging portfolio, Dennis's experience will be instrumental in helping us execute our ambitions and create long-term value for patients, partners and shareholders."
For more information, please contact:
Dan Schneider President and CEO Photocure ASA Email: ds@photocure.com
Priyam Shah Vice President Investor Relations Tel: +17176815072 Email: priyam.shah@photocure.com
Media and IR enquiries:
Geir Bjørlo Corporate Communications (Norway) Tel: +47 91540000 Email: geir.bjorlo@corpcom.no
About Photocure ASA Photocure is a commercial diagnostic company with global reach, committed to driving progress in uro-oncology precision diagnostics, delivering meaningful advances for patients with urological cancers. Our unique core technology has led to better health outcomes for patients worldwide. The company aims to provide an array of transformative solutions that help physicians with timely diagnostic information, to inform more personalized decisions on how best to manage each individual patient. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit www.photocure.com/news
This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act and Euronext Oslo Rule Book II - Issuer Rules.